Welcome to our dedicated page for Mural Oncology PLC SEC filings (Ticker: MURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical data tables, complex risk factors, and pages of cytokine biology make the Mural Oncology annual report 10-K simplified anything but simple. If you鈥檙e combing through nemvaleukin trial details or cash-runway notes, you know the frustration of translating biotech jargon into plain language.
That鈥檚 why Stock Titan pairs every Mural Oncology quarterly earnings report 10-Q filing, 8-K trial update, and Mural Oncology insider trading Form 4 transactions with AI-powered summaries. Our engine surfaces R&D spend trends, highlights FDA milestone disclosures, and flags liquidity warnings, giving you Mural Oncology SEC filings explained simply. Need to understand dilution risk from the latest offering? A click pulls up Mural Oncology 8-K material events explained with side-by-side comparisons to prior statements, while charted metrics turn dense numbers into clear visuals鈥攁 complete Mural Oncology earnings report filing analysis in minutes.
AG真人官方-time alerts mean you see Mural Oncology Form 4 insider transactions real-time, track each Mural Oncology executive stock transactions Form 4, and review the Mural Oncology proxy statement executive compensation without waiting for end-of-day feeds. Whether you鈥檙e hedge-fund analyst, sell-side researcher, or individual investor focused on understanding Mural Oncology SEC documents with AI, our coverage of every form鈥�10-K, 10-Q, 8-K, S-3, plus exhibits鈥攌eeps you ahead of market-moving details. Complex biotech filings decoded, pipeline milestones tracked, decisions made faster.
Mural Oncology plc (MURA) Q2-25 10-Q highlights
The company has halted all clinical and pre-clinical development after nemvaleukin failed to meet the primary OS endpoint in the Phase 3 ARTISTRY-7 trial and follow-on Phase 2 data were disappointing. Management implemented a ~90 % workforce reduction, recorded $17.5 m of restructuring and impairment charges in Q2, and is exploring strategic alternatives including a possible sale or liquidation.
Financially, cash & equivalents fell to $77.1 m from $115.5 m at year-end as operating cash burn reached $68.2 m YTD. Marketable securities were liquidated, cutting total assets to $87.6 m (-48 %). Equity declined to $58.8 m vs $140.5 m. Q2 operating loss widened to $48.8 m (vs $34.3 m LY) driven by restructuring. Net loss was $48.0 m, or 鈥�$2.78/sh; six-month loss is $81.1 m (鈥�$4.71/sh). R&D expense dropped 15 % YoY to $23.3 m as programs shut down, while G&A rose to $8.1 m.
The 10-Q states that, despite cost cuts, substantial doubt exists about the company鈥檚 ability to continue as a going concern beyond 12 months absent additional funding or a transaction. An ATM facility for up to $75 m was put in place in March, but no shares have been sold. Lease liabilities total $5.2 m through 2026, partly offset by sub-lease income.
Key investor takeaways:
- Pipeline effectively terminated; no revenue-generating assets.
- $77 m cash provides limited optionality while the board seeks strategic alternatives.
- Going-concern warning, large accumulated deficit ($240.5 m) and equity erosion underscore high risk.
Form 4 overview: On 22 Jul 2025, Maiken Keson-Brookes, Chief Legal Officer & Secretary of Mural Oncology plc (MURA), sold 2,572 ordinary shares at a weighted-average price of $2.48 (price band $2.46-$2.51). The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on 20 Sep 2024.
Following the transaction, the insider directly owns 68,834 shares, which include 62,203 unvested RSUs. No derivative securities were reported and no other insiders participated. The filing indicates direct ownership status and contains the standard acknowledgements and signatures required under Section 16.
Manhattan Associates (MANH) filed a Form 8-K on 22 Jul 2025 to furnish its Q2-25 earnings press release (Exhibit 99.1). No revenue or EPS figures are included in the filing; instead, it describes the company鈥檚 preferred non-GAAP metrics: adjusted operating income & margin, adjusted tax provision, adjusted net income and adjusted diluted EPS.
The adjusted results exclude three items:
- Equity-based compensation and related tax effects
- An unusually large health-insurance claim (net of recoveries)
- Restructuring charges from a 2025 workforce reduction aimed at matching services capacity with softer demand
Management says these exclusions better reflect operating performance, guide internal decision-making and align executive incentives. The disclosure is made under Item 2.02; because the exhibit is 鈥渇urnished鈥� rather than 鈥渇iled,鈥� it is not subject to Section 18 liability.
Agios Pharmaceuticals, Inc. (AGIO) 鈥� Form 144
An affiliate has filed a Form 144 to sell up to 11,914 common shares through Morgan Stanley Smith Barney on or about 07/09/2025. The shares have an aggregate market value of $452,631.92 and represent roughly 0.02 % of the company鈥檚 57,915,199 shares outstanding, indicating a very limited effect on the public float.
The seller acquired the shares on the same date via a cash-settled stock-option exercise. In the prior three months the same individual sold 7,000 shares (4,091 on 07/01/2025 and 2,909 on 06/24/2025) for total gross proceeds of $237,341.32.
The filing states that the insider is unaware of any undisclosed material adverse information and is complying with Rule 144 sale restrictions. Given the modest share count involved, the proposed disposition appears to be a routine liquidity move with minimal expected market impact.
Agios Pharmaceuticals, Inc. (AGIO) 鈥� Form 144
An affiliate has filed a Form 144 to sell up to 11,914 common shares through Morgan Stanley Smith Barney on or about 07/09/2025. The shares have an aggregate market value of $452,631.92 and represent roughly 0.02 % of the company鈥檚 57,915,199 shares outstanding, indicating a very limited effect on the public float.
The seller acquired the shares on the same date via a cash-settled stock-option exercise. In the prior three months the same individual sold 7,000 shares (4,091 on 07/01/2025 and 2,909 on 06/24/2025) for total gross proceeds of $237,341.32.
The filing states that the insider is unaware of any undisclosed material adverse information and is complying with Rule 144 sale restrictions. Given the modest share count involved, the proposed disposition appears to be a routine liquidity move with minimal expected market impact.
DocuSign, Inc. (DOCU) 鈥� Insider Activity Filing (Form 4)
Chief Financial Officer Blake Jeffrey Grayson reported two open-market sales of DocuSign common stock on 18 June 2025 executed under a pre-arranged Rule 10b5-1 trading plan.
- Total shares sold: 15,143 (13,208 at $74.27-$75.22 and 1,935 at $75.33-$75.63).
- Estimated gross proceeds: 鈮� $1.13 million.
- Remaining beneficial ownership: 110,723 shares held directly.
- No derivative transactions or new option grants were reported.
The filing reflects routine diversification by the CFO while maintaining a substantial equity stake, limiting potential governance concerns. Investors may monitor subsequent insider activity to assess sentiment trends.
FAQ
What is the current stock price of Mural Oncology PLC (MURA)?
What is the market cap of Mural Oncology PLC (MURA)?
What is the core focus of Mural Oncology PLC?
How does nemvaleukin function in cancer therapy?
What innovative strategies are used in their therapy development?
What are the other key programs in Mural Oncology's pipeline?
How is the company addressing dosing and administration challenges?
What sets Mural Oncology apart from traditional cytokine therapies?
How does Mural Oncology maintain its position in a competitive market?
Why is protein engineering crucial for their treatment strategy?
